EUVIMEDEUVIMED entdecken
Fallbericht

Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access

Yara E Tovar, John Y Jun

Journal of Health Care for the Poor and Underserved · 2026-11 · 37 (4) · 1446-1450

DOI: 10.1353/hpu.2026.a1005877 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Health Care for the Poor and Underserved, 2026-11. Verfasst von Yara E Tovar und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Tirzepatide, Medicaid, Health Services Accessibility, Diabetes Mellitus, Type 2.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medicaid beneficiaries often face barriers to accessing evidence-based metabolic therapies, even as U.S. Food and Drug Administration (FDA) indications for agents such as tirzepatide expand. Although tirzepatide is approved for type 2 diabetes (T2D), obstructive sleep apnea (OSA), and obesity, some state Medicaid programs apply diagnosis-based restrictions that do not align with FDA labeling or clinical practice. We describe a 34-year-old woman with obesity, T2D, and OSA who experienced repeated denials for tirzepatide under Ohio Medicaid, despite meeting FDA-approved criteria for multiple indications. Diagnostic silos, contradictory exclusion rules, and inconsistent authorization pathways delayed treatment for six months, requiring multiple appeals, peer-to-peer reviews, and a state hearing before approval. This case illustrates how rigid coverage criteria can override clinical judgment and impede timely treatment. Variation across Medicaid programs limits access to glucagon-like peptide-1 (GLP-1)–based therapies. Aligning coverage with FDA labeling is essential to ensuring equitable, patient-centered care for underserved populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirzepatideMedicaidHealth Services AccessibilityDiabetes Mellitus, Type 2Insurance CoverageHypoglycemic AgentsHumansFemaleUnited StatesAdultOhioSleep Apnea, ObstructiveObesity

Substanzen

TirzepatideHypoglycemic Agents

Zitieren

APA

Tovar, Y. E., & Jun, J. Y. (2026). Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access. Journal of Health Care for the Poor and Underserved, 37(4), 1446-1450. https://doi.org/10.1353/hpu.2026.a1005877

Vancouver

Tovar YE, Jun JY. Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access. Journal of Health Care for the Poor and Underserved. 2026;37(4):1446-1450. doi:10.1353/hpu.2026.a1005877

BibTeX
@article{Tovar2026,
  author = {Tovar, Yara E and Jun, John Y},
  title = {Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access},
  journal = {Journal of Health Care for the Poor and Underserved},
  year = {2026},
  volume = {37},
  number = {4},
  pages = {1446--1450},
  doi = {10.1353/hpu.2026.a1005877}
}
Kostenlos starten →